文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

CRISPR-Cas在感染性疾病诊断与治疗中的应用

CRISPR-Cas in Diagnostics and Therapy of Infectious Diseases.
PubMed 文献 · J Infect Dis · 2022-01-01

本综述概述了CRISPR-Cas系统及其在感染性疾病研究中的应用,包括改进诊断、干预抗菌药物耐药和治愈慢性感染,并探讨了该技术当前面临的挑战及临床转化所需的改进。

要点

  • CRISPR-Cas源自细菌适应性免疫系统,可对包括人类和微生物在内的任何基因组进行编辑。
  • 已有研究探索该技术用于感染性疾病诊断、干预抗菌药物耐药及治愈慢性感染。
  • 综述还讨论了该技术当前面临的挑战及为临床采用所需的改进。

核心结论

  • 本综述概述了CRISPR-Cas系统及其在感染性疾病研究中的应用,并探讨了该技术当前面临的挑战及为临床采用所需的改进。

研究设计与样本

  • 综述类文章,检索范围原文未报告。

主要发现

  • CRISPR-Cas是细菌天然存在的适应性免疫系统,已被开发为对包括人类和微生物在内的任何感兴趣基因组进行基因组改变的工具。
  • 已有若干研究探讨如何将该技术用于感染性疾病以改进诊断、干预抗菌药物耐药和治愈慢性感染。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infectious diseases are a major threat to the global health. The rise in antimicrobial-resistant organisms, incurable chronic infections, and an increasing demand for rapid accurate diagnostics have prompted researchers to experiment with new approaches. Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein (Cas) is a naturally occurring adaptive immune system in bacteria that has been developed as a tool for performing genomic alterations in any genome of interest, including humans and microbes. Accordingly, several studies have been conducted to investigate how the technology can be utilized in infectious diseases to improve diagnostics, disrupt antimicrobial resistance, and cure chronic infections. This review provides an overview of the CRISPR-Cas system and how it has been applied in studies on infectious diseases. The review also investigates the current challenges of the technology and the improvements that are needed for the platform to be adopted for clinical use in patients.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gleerup JL, Mogensen TH. CRISPR-Cas in Diagnostics and Therapy of Infectious Diseases. J Infect Dis. 2022. PMID: 35446391. doi:10.1093/infdis/jiac145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。